Europos Sąjunga - prancūzų - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - agents antinéoplasiques - sprycel est indiqué pour le traitement des patients pédiatriques avec:nouvellement diagnostiqués porteurs du chromosome philadelphie positive leucémie myéloïde chronique en phase chronique (lmc ph+ cp) ou de la lmc ph+ cp résistants ou intolérants à un traitement antérieur incluant l'imatinib. nouvellement diagnostiqués ph+ de leucémie aiguë lymphoblastique (all) en combinaison avec la chimiothérapie. sprycel est indiqué pour le traitement de patients adultes atteints:nouvellement diagnostiqué le chromosome de philadelphie positif (ph+) leucémie myéloïde chronique (lmc) en phase chronique;chronique, accélérée ou blastique de la lmc en phase avec résistance ou à une intolérance à un traitement antérieur incluant l'imatinib mésilate;ph+ de leucémie aiguë lymphoblastique (all) et lymphoïdes explosion de la lmc à la résistance ou à une intolérance à un traitement antérieur. sprycel est indiqué pour le traitement des patients pédiatriques avec:nouvellement diagnostiqués lmc ph+ en phase chronique (lmc ph+-cp) ou de la lmc ph+-cp résistants ou intolérants à un traitement antérieur incluant l'imatinib.

Europos Sąjunga - prancūzų - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - paclitaxel - breast neoplasms; pancreatic neoplasms; carcinoma, non-small-cell lung - agents antinéoplasiques - abraxane en monothérapie est indiqué pour le traitement du cancer du sein métastatique chez les patients adultes qui ont échoué dans le traitement de première intention de la maladie métastatique et pour qui le traitement standard contenant des anthracyclines n'est pas indiqué. l'abraxane en combinaison avec la gemcitabine est indiquée pour le traitement de première ligne des patients adultes atteints d'un adénocarcinome métastatique du pancréas. l'abraxane en association avec le carboplatine est indiqué pour le traitement de première ligne de la non-small cell lung cancer chez les patients adultes qui ne sont pas des candidats pour la chirurgie potentiellement curative et/ou à une radiothérapie.

Europos Sąjunga - prancūzų - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - belatacept - graft rejection; kidney transplantation - immunosuppresseurs - nulojix, in combination with corticosteroids and a mycophenolic acid (mpa), is indicated for prophylaxis of graft rejection in adult recipients of a renal transplant.

Europos Sąjunga - prancūzų - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - azacitidine - leucémie, myéloïde, aiguë - agents antinéoplasiques - onureg is indicated as maintenance therapy in adult patients with acute myeloid leukaemia (aml) who achieved complete remission (cr) or complete remission with incomplete blood count recovery (cri) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (hsct).

Europos Sąjunga - prancūzų - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - la thalidomide - le myélome multiple - immunosuppresseurs - thalidomide bms in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged >/= 65 years or ineligible for high dose chemotherapy. thalidomide bms is prescribed and dispensed according to the thalidomide celgene pregnancy prevention programme (see section 4.

Europos Sąjunga - prancūzų - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - azacitidine - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - agents antinéoplasiques - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.

Europos Sąjunga - prancūzų - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - agents antinéoplasiques - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.

Europos Sąjunga - prancūzų - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ozanimod de chlorhydrate de - multiple sclerosis, relapsing-remitting; colitis, ulcerative - immunosuppresseurs - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

Europos Sąjunga - prancūzų - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - agents antinéoplasiques - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Europos Sąjunga - prancūzų - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - agents antinéoplasiques - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.